In a recent survey, Guilin Sanjin said that currently the company's first-line varieties, the watermelon cream series and the Sanjin tablet series, account for close to 80% of sales revenue, and are currently undergoing secondary product development, such as introducing new dosage forms, increasing indications, combined medication, etc. We believe that the sales volume of the company's products in the corresponding oropharyngeal and urinary system markets still has the potential to increase. The company now accounts for a large share of OTC, and the next step is to expand sales on the hospital side.
桂林三金：公司现在OTC占比很大，下一步争取扩大在医院端的销量
Guilin Sanjin: The company now accounts for a large share of OTC. The next step is to increase sales on the hospital side
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.